Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYHA121-28
- Development stage
- Unknown
- Lead developer
- CSPC NBP Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SYHA121-28 (also known as HA121-28) is an orally bioavailable, small-molecule multi-targeting tyrosine kinase inhibitor (TKI) developed by CSPC ZhongQi Pharmaceutical Technology (a subsidiary of CSPC Pharmaceutical Group). It primarily targets rearranged during transfection (RET) fusions, while also selectively inhibiting epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor-2 (VEGFR-2), and fibroblast growth factor receptors 1–3 (FGFR1-3). By blocking these signaling pathways, SYHA121-28 exerts dual efficacy, inhibiting both tumor cell proliferation and tumor angiogenesis. It is being clinically evaluated for the treatment of advanced solid tumors, particularly RET fusion-positive non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and biliary tract cancer.
- Other names
- EGFR/VEGFR/RET inhibitor HA121-28
02
Targets
EGFR (Epidermal growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on SYHA121-28.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYHA121-28.